Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neisseria meningitidis group W-135 polysaccharide-tetanus toxoid conjugate vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis group W-135 polysaccharide-tetanus toxoid conjugate vaccine is a specialized vaccine component developed by Sanofi for the prevention of invasive meningococcal disease. It consists of the purified capsular polysaccharide of serogroup W-135 Neisseria meningitidis covalently linked to a tetanus toxoid carrier protein. This conjugation process is essential for converting the polysaccharide into a T-cell dependent antigen, thereby inducing high-affinity antibodies and immunological memory, which are not typically achieved with pure polysaccharide vaccines. This specific conjugate is a key constituent of Sanofi's quadrivalent meningococcal vaccine, MenQuadfi (MenACYW-TT), which provides broad protection against serogroups A, C, Y, and W-135 and was approved by the FDA in 2020 for use in individuals 2 years of age and older.
- Other names
- Meningococcal group W-135 conjugate vaccineMenW-TT conjugate
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on neisseria meningitidis group W-135 polysaccharide-tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neisseria meningitidis group W-135 polysaccharide-tetanus toxoid conjugate vaccine.